Pyxis Oncology Shares Slide on Steeper 1Q Loss

Dow Jones05-15

By Kelly Cloonan

Shares of Pyxis Oncology declined after the company logged a steeper first-quarter loss, narrowly missing Wall Street's expectations.

The stock slid 15% to $2.24 on Thursday. Shares have surged 94% year to date.

The company, which is developing cancer treatments, posted a loss of $23.3 million, or 37 cents a share, compared with a loss of $21.2 million, or 35 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 36 cents a share.

The company said it expects milestones for its lead candidate, micvotabart pelidotin, this year, and remains on track to share updated monotherapy data in the middle of 2026 as well as updated combination data in the second half of the year.

Micvotabart pelidotin is designed to treat solid tumors, targeting a component of the tumor extracellular matrix.

The company expects to have cash runway into the fourth quarter.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

May 14, 2026 13:51 ET (17:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635742250?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 01:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635742250","market":"fut","top_or_hot":-1,"title":"Pyxis Oncology Shares Slide on Steeper 1Q Loss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/PYXS\">Pyxis Oncology</a> declined after the company logged a steeper first-quarter loss, narrowly missing Wall Street's expectations. \n</p>\n<p>\n  The stock slid 15% to $2.24 on Thursday. Shares have surged 94% year to date. \n</p>\n<p>\n  The company, which is developing cancer treatments, posted a loss of $23.3 million, or 37 cents a share, compared with a loss of $21.2 million, or 35 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 36 cents a share. \n</p>\n<p>\n  The company said it expects milestones for its lead candidate, micvotabart pelidotin, this year, and remains on track to share updated monotherapy data in the middle of 2026 as well as updated combination data in the second half of the year. \n</p>\n<p>\n  Micvotabart pelidotin is designed to treat solid tumors, targeting a component of the tumor extracellular matrix. \n</p>\n<p>\n  The company expects to have cash runway into the fourth quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 14, 2026 13:51 ET (17:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pyxis Oncology Shares Slide on Steeper 1Q Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPyxis Oncology Shares Slide on Steeper 1Q Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-15 01:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/PYXS\">Pyxis Oncology</a> declined after the company logged a steeper first-quarter loss, narrowly missing Wall Street's expectations. \n</p>\n<p>\n  The stock slid 15% to $2.24 on Thursday. Shares have surged 94% year to date. \n</p>\n<p>\n  The company, which is developing cancer treatments, posted a loss of $23.3 million, or 37 cents a share, compared with a loss of $21.2 million, or 35 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 36 cents a share. \n</p>\n<p>\n  The company said it expects milestones for its lead candidate, micvotabart pelidotin, this year, and remains on track to share updated monotherapy data in the middle of 2026 as well as updated combination data in the second half of the year. \n</p>\n<p>\n  Micvotabart pelidotin is designed to treat solid tumors, targeting a component of the tumor extracellular matrix. \n</p>\n<p>\n  The company expects to have cash runway into the fourth quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 14, 2026 13:51 ET (17:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2635742250","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635742250","pubTimestamp":1778781060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Pyxis Oncology declined after the company logged a steeper first-quarter loss, narrowly missing Wall Street's expectations.The stock slid 15% to $2.24 on Thursday. Shares have surged 94% year to date.The company, which is developing cancer treatments, posted a loss of $23.3 million, or 37 cents a share, compared with a loss of $21.2 million, or 35 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 36 cents a share.The company said it expects milestones for its lead candidate, micvotabart pelidotin, this year, and remains on track to share updated monotherapy data in the middle of 2026 as well as updated combination data in the second half of the year.Micvotabart pelidotin is designed to treat solid tumors, targeting a component of the tumor extracellular matrix.The company expects to have cash runway into the fourth quarter.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PYXS":"Pyxis Oncology, Inc."},"translate_title":"Pyxis Oncology股价因第一季度亏损加剧而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PYXS":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Pyxis Oncology declined after the company logged a steeper first-quarter loss, narrowly missing Wall Street's expectations. \n\n\n  The stock slid 15% to $2.24 on Thursday. Shares have surged 94% year to date. \n\n\n  The company, which is developing cancer treatments, posted a loss of $23.3 million, or 37 cents a share, compared with a loss of $21.2 million, or 35 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 36 cents a share. \n\n\n  The company said it expects milestones for its lead candidate, micvotabart pelidotin, this year, and remains on track to share updated monotherapy data in the middle of 2026 as well as updated combination data in the second half of the year. \n\n\n  Micvotabart pelidotin is designed to treat solid tumors, targeting a component of the tumor extracellular matrix. \n\n\n  The company expects to have cash runway into the fourth quarter. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2026 13:51 ET (17:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635742250","isCrawlerRequest":true}